List of Uptravi drug patents
Uptravi is owned by Actelion.
Uptravi contains Selexipag.
Uptravi has a total of 6 drug patents out of which 0 drug patents have expired.
Uptravi was authorised for market use on 29 July, 2021.
Uptravi is available in powder;intravenous dosage forms.
Uptravi can be used as method of treating pulmonary arterial hypertension comprising administering selexipag in combination with the endothelin receptor antagonist macitentan, method of treating pulmonary arterial hypertension comprising administering a tablet containing selexipag, method of treating pulmonary arterial hypertension comprising administering a pharmaceutical composition comprising selexipag, method of treating pulmonary arterial hypertension comprising administering a solid preparation containing selexipag, method of treating pulmonary arterial hypertension comprising administering a crystalline form of selexipag.
The generics of Uptravi are possible to be released after 01 December, 2036.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7205302 | ACTELION | Heterocyclic compound derivatives and medicines |
Oct, 2026
(3 years from now) | |
| US8791122 | ACTELION | Form-I crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide and method for producing the same |
Aug, 2030
(7 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9173881 | ACTELION | Therapeutic compositions containing macitentan |
Aug, 2029
(6 years from now) | |
| US9284280 | ACTELION | Use of form-I crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide |
Jun, 2030
(7 years from now) | |
| US10828298 | ACTELION | Pharmaceutical composition containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy]-N-(methylsulfonyl)acetamide |
Dec, 2036
(13 years from now) | |
| US10821108 | ACTELION | Pharmaceutical composition containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide |
Dec, 2036
(13 years from now) | |
Drugs and Companies using SELEXIPAG ingredient
Market Authorisation Date: 29 July, 2021
Treatment: Method of treating pulmonary arterial hypertension comprising administering selexipag in combination with the endothelin receptor antagonist macitentan; Method of treating pulmonary arterial hypertension comprising administering a crystalline form of selexipag; Method of treating pulmonary arterial hypertension comprising administering a tablet containing selexipag; Method of treating pulmonary arterial hypertension comprising administering a solid preparation containing selexipag; Method of treating pulmonary arterial hypertension comprising administering a pharmaceutical composition comprising selexipag
Dosage: POWDER;INTRAVENOUS
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic